Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | PKM | P14618 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | RECQL | P46063 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | CTSL | P07711 | 1/20 | 0.49 |
| ▸ | USP2 | O75604 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.47 |
| ▸ | FES | P07332 | 1/20 | 0.46 |
| ▸ | RET | P07949 | 1/20 | 0.46 |
| ▸ | MARK3 | P27448 | 1/20 | 0.46 |
| ▸ | TYK2 | P29597 | 1/20 | 0.46 |
| ▸ | FLT4 | P35916 | 1/20 | 0.46 |
| ▸ | SYK | P43405 | 1/20 | 0.46 |
| ▸ | CLK2 | P49760 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL13584132 | 0.99 | ALDH1A1 (0.51) | ALDH1A1PKMKMT2ARECQLHTT | |
| SCHEMBL19493948 | 0.83 | KMT2A (0.47) | ALDH1A1PKMKMT2ARECQLHTT | |
| SCHEMBL30165326 | 0.82 | KEAP1 (0.59) | ALDH1A1RECQLHTTSMN1; SMN2CTSL | |
| SCHEMBL13584673 | 0.82 | KEAP1 (0.59) | ALDH1A1RECQLHTTSMN1; SMN2CTSL | |
| SCHEMBL13584425 | 0.82 | KMT2A (0.46) | ALDH1A1KMT2ASMN1; SMN2GAACYP2D6 | |
| Hydrochloric Acid SCHEMBL13583573 | 0.81 | KEAP1 (0.57) | ALDH1A1RECQLHTTSMN1; SMN2CTSL | |
| SCHEMBL29055220 | 0.81 | RECQL (0.62) | ALDH1A1PKMKMT2ARECQLHTT | |
| Hydrochloric Acid SCHEMBL13584530 | 0.80 | KMT2A (0.45) | ALDH1A1KMT2ASMN1; SMN2GAACYP2D6 | |
| SCHEMBL14289021 | 0.80 | ALDH1A1 (0.60) | ALDH1A1PKMKMT2ARECQLHTT | |
| SCHEMBL17777457 | 0.79 | ALDH1A1 (0.51) | ALDH1A1PKMKMT2ARECQLHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180256520-A1 | BIGUANIDE DERIVATIVE, A PREPARATION METHOD THEREOF, AND A PHARMACEUTICAL COMPOSITION CONTAINING THE BIGUANIDE DERIVATIVE AS AN ACTIVE INGREDIENT | HANALL BIOPHARMA CO., LTD. (KR) | 2018-09-13 | — | — | US | claimed |
| US-9993446-B2 | Biguanide derivative, a preparation method thereof, and a pharmaceutical composition containing the biguanide derivative as an active ingredient | IMMUNOMET THERAPEUTICS INC. (US) | 2018-06-12 | — | — | US | claimed |
| US-20160317478-A1 | Biguanide Derivative, A Preparation Method Thereof, And A Pharmaceutical Composition Containing The Biguanide Derivative As An Active Ingredient | IMMUNOMET THERAPEUTICS INC. | 2016-11-03 | — | — | US | claimed |
| US-9416098-B2 | Biguanide derivative, a preparation method thereof and a pharmaceutical composition containing the biguanide derivative as an active ingredient | IMMUNOMET THERAPEUTICS INC. (US) | 2016-08-16 | — | — | US | claimed |
| EP-2522653-A2 | BIGUANIDE DERIVATIVE, A PREPARATION METHOD THEREOF AND A PHARMACEUTICAL COMPOSITION CONTAINING THE BIGUANIDE DERIVATIVE AS AN ACTIVE INGREDIENT | HanAll Biopharma Co., Ltd. (KR) | 2012-11-14 | — | — | EP | claimed |
| US-20120283299-A1 | Biguanide Derivative, A Preparation Method Thereof And A Pharmaceutical Composition Containing The Biguanide Derivative As An Active Ingredient | HANALL BIOPHARMA CO., LTD. (KR) | 2012-11-08 | — | — | US | claimed |
| US-10376480-B2 | Biguanide derivative, a preparation method thereof, and a pharmaceutical composition containing the biguanide derivative as an active ingredient | IMMUNOMET THERAPEUTICS INC. (US) | 2019-08-13 | — | — | US | disclosed |
| US-10376480-B2 | Biguanide derivative, a preparation method thereof, and a pharmaceutical composition containing the biguanide derivative as an active ingredient | IMMUNOMET THERAPEUTICS INC. (US) | 2019-08-13 | — | — | US | disclosed |
| US-20180256520-A1 | BIGUANIDE DERIVATIVE, A PREPARATION METHOD THEREOF, AND A PHARMACEUTICAL COMPOSITION CONTAINING THE BIGUANIDE DERIVATIVE AS AN ACTIVE INGREDIENT | HANALL BIOPHARMA CO., LTD. (KR) | 2018-09-13 | — | — | US | disclosed |
| US-9993446-B2 | Biguanide derivative, a preparation method thereof, and a pharmaceutical composition containing the biguanide derivative as an active ingredient | IMMUNOMET THERAPEUTICS INC. (US) | 2018-06-12 | — | — | US | disclosed |
| US-9993446-B2 | Biguanide derivative, a preparation method thereof, and a pharmaceutical composition containing the biguanide derivative as an active ingredient | IMMUNOMET THERAPEUTICS INC. (US) | 2018-06-12 | — | — | US | disclosed |
| US-20160317478-A1 | Biguanide Derivative, A Preparation Method Thereof, And A Pharmaceutical Composition Containing The Biguanide Derivative As An Active Ingredient | IMMUNOMET THERAPEUTICS INC. | 2016-11-03 | — | — | US | disclosed |
| US-20160317478-A1 | Biguanide Derivative, A Preparation Method Thereof, And A Pharmaceutical Composition Containing The Biguanide Derivative As An Active Ingredient | IMMUNOMET THERAPEUTICS INC. | 2016-11-03 | — | — | US | disclosed |
| US-9416098-B2 | Biguanide derivative, a preparation method thereof and a pharmaceutical composition containing the biguanide derivative as an active ingredient | IMMUNOMET THERAPEUTICS INC. (US) | 2016-08-16 | — | — | US | disclosed |
| US-9416098-B2 | Biguanide derivative, a preparation method thereof and a pharmaceutical composition containing the biguanide derivative as an active ingredient | IMMUNOMET THERAPEUTICS INC. (US) | 2016-08-16 | — | — | US | disclosed |
| US-9416098-B2 | Biguanide derivative, a preparation method thereof and a pharmaceutical composition containing the biguanide derivative as an active ingredient | IMMUNOMET THERAPEUTICS INC. (US) | 2016-08-16 | — | — | US | disclosed |
| EP-2522653-A2 | BIGUANIDE DERIVATIVE, A PREPARATION METHOD THEREOF AND A PHARMACEUTICAL COMPOSITION CONTAINING THE BIGUANIDE DERIVATIVE AS AN ACTIVE INGREDIENT | HanAll Biopharma Co., Ltd. (KR) | 2012-11-14 | — | — | EP | disclosed |
| US-20120283299-A1 | Biguanide Derivative, A Preparation Method Thereof And A Pharmaceutical Composition Containing The Biguanide Derivative As An Active Ingredient | HANALL BIOPHARMA CO., LTD. (KR) | 2012-11-08 | — | — | US | disclosed |
| US-20120283299-A1 | Biguanide Derivative, A Preparation Method Thereof And A Pharmaceutical Composition Containing The Biguanide Derivative As An Active Ingredient | HANALL BIOPHARMA CO., LTD. (KR) | 2012-11-08 | — | — | US | disclosed |
| US-20120283299-A1 | Biguanide Derivative, A Preparation Method Thereof And A Pharmaceutical Composition Containing The Biguanide Derivative As An Active Ingredient | HANALL BIOPHARMA CO., LTD. (KR) | 2012-11-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180256520-A1 | BIGUANIDE DERIVATIVE, A PREPARATION METHOD THEREOF, AND A PHARMACEUTICAL COMPOSITION CONTAINING THE BIGUANIDE DERIVATIVE AS AN ACTIVE INGREDIENT | PRKAG1, PRKAG3, PRKAG2 | ALDH1A1 3161/4885PKM 815/4885KMT2A 2501/4885 |
| US-20120283299-A1 | Biguanide Derivative, A Preparation Method Thereof And A Pharmaceutical Composition Containing The Biguanide Derivative As An Active Ingredient | PRKAG1, PRKAG2, PRKAG3 | ALDH1A1 3071/4885PKM 883/4885KMT2A 2514/4885 |
| US-20160317478-A1 | Biguanide Derivative, A Preparation Method Thereof, And A Pharmaceutical Composition Containing The Biguanide Derivative As An Active Ingredient | PRKAG1, PRKAG3, PRKAG2 | ALDH1A1 3441/4885PKM 818/4885KMT2A 2430/4885 |
| US-10376480-B2 | Biguanide derivative, a preparation method thereof, and a pharmaceutical composition containing the biguanide derivative as an active ingredient | PRKAG1, PRKAG3, PRKAG2 | ALDH1A1 3161/4885PKM 815/4885KMT2A 2501/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.